Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Switching to Intranasal Esketamine Maintains the Antidepressant Response to Intravenous Racemic Ketamine Administration: A Case Series of 10 Patients


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT04856124

Organisation Name: Psych Atlanta

Overal Status: Completed

Start Date: September 1, 2018

Last Update: April 23, 2021

Lead Sponsor: Psych Atlanta

Brief Summary: This study aims to assess the efficacy and safety of intranasal esketamine as maintenance antidepressant therapy in patients who have demonstrated clinical improvement with off-label intravenous racemic ketamine for treatment-resistant depression.

Conditions:
  • Treatment Resistant Depression


Total execution time in seconds: 0.16733312606812